Article summary
The European Commission has approved, under Regulation (EC) 139/2004 (the EU Merger Regulation), the acquisition of US-based Alexion Pharmaceuticals Inc (Alexion) by UK's AstraZeneca plc (AstraZeneca) for $US 39bn. Although both are global pharmaceutical companies, Alexion focuses on the treatment of rare diseases and AstraZeneca focuses on common diseases. The Commission concluded that the merger would have limited impact on the markets involved.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial